FindTrial
Sign In

Establishing clinically meaningful severity cutoffs for severity scores in Pemphigus (PDAI and ABSIS) using physician assessed severity as the standard

Clinical interpretation of Pemphigus Disease Area Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) using anchor-based approach - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/02/080660
Enrollment
50
Registered
2025-02-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L102- Pemphigus foliaceous Health Condition 2: L100- Pemphigus vulgaris

Interventions

None listed

Sponsors

AIIMS New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients more than 18 years with active pemphigus vulgaris or foliaceous diagnosed on the basis of clinical features and histopathology New or relapsed cases Any disease severity

Exclusion criteria

Exclusion criteria: Children Pemphigus patients in consolidation phase or remission

Design outcomes

Primary

MeasureTime frame
PDAI, ABSIS scoresTimepoint: 3-4 weeks—

Secondary

MeasureTime frame
PDAI, ABSIS scores cut offs with respect to Investigator Global Assessment PDAI, ABSIS cut offs using starting dose of prednisolone as anchor Inter- rater agreement of Physician Global Assessment Correlation of disease severity scores with PGA and quality of life scales Patient factors affecting Quality of life in pemphigusTimepoint: 3-4 weeks—

Countries

India

Contacts

Public ContactSumayya Mehaboob

AIIMS New Delhi

sumayyamehaboob1070@gmail.com9400162196

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026